Prostate cancer, the second most frequent cancer and the fifth leading cause of cancer-specific mortality among men worldwide (1), is increasingly being detected with serum prostate-specific antigen (PSA) screening, especially the localized ones (2). This evidence concerns the gene KLK3 and prostate carcinoma.